Sucampo have announced results from 3 open-labeled, long-term clinical trials of lubiprostone (AMITIZA) in patients with Chronic Idiopathic Constipation (CIC).
Filed under: Uncategorized | Tagged: amitiza, chloride channel, cl channel, ClC-2, lubiprostone, Sucampo | Leave a Comment »
Chloride channel agonist Amitiza (lubiprostone) had been shown to significantly relieve symptoms of Irritable Bowel Syndrome with Constipation (IBS-C).
Filed under: Ion Channel | Tagged: amitiza, chloride channel, CIC-2, CIC2, cl channel, lubiprostone, RU-0211, RU0211, SPI-0211, SPI0211, Sucampo, takeda | Leave a Comment »
The FDA has approved Amitiza for the addtitional indication of irritable bowel syndrome with constipation (IBS-C) in women 18 years of age or older. It was previously launched in the US forchronic idiopathic constipation in 2006
Filed under: Ion Channel | Tagged: amitiza, chloride channel, CIC-2, CIC2, cl channel, lubiprostone, RU-0211, RU0211, SPI-0211, SPI0211, Sucampo, takeda | Leave a Comment »
